In 2010, a TKI targeting ALK and c-MET, crizotinib18 (also called PF-02341066), was authorized in clinical trials as a second-line therapy for advanced stage NSCLC harboring EML4–ALK. The gene discussed is ALK; the disease is non-small cell lung carcinoma.